![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Blueprint Medicines’ Gavreto Approved for Non-Small Cell Lung Cancer
Blueprint Medicines’ Gavreto Approved for Non-Small Cell Lung Cancer
![Purple_Approved_Stamp.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/Purple_Approved_Stamp.gif?t=1576639773&width=430)
September 9, 2020
The FDA has approved Blueprint Medicines’ Gavreto (pralsetinib) for adults with metastatic rearranged during transfection (RET), fusion-positive non-small cell lung cancer.
The accelerated approval was based on a phase 1/2 clinical trial, in which Gavreto demonstrated an overall response rate of 57 percent among patients previously treated with chemotherapy, with 5.7 percent achieving a complete response. In addition, 70 percent of patients who were not previously treated achieved a response, with 11 percent achieving a complete response.
Massachusetts-based Blueprint Medicines and Genentech will co-commercialize Gavreto in the U.S. Roche, Genentech’s parent company, will commercialize the product outside of the U.S., excluding China.
Upcoming Events
-
21Oct